Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to calm inflammation in kidney disease patients

NCT ID NCT06362759

Disease control Sponsor: Tourmaline Bio, Inc., a Novartis Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tested a drug called TOUR006 in 143 adults with chronic kidney disease and high levels of a protein linked to inflammation (hs-CRP). The goal was to see if monthly or quarterly shots could safely lower inflammation. The study is complete, and results will show if the drug helps control disease-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

143 people

The number who actually took part.

Started

May 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years at time of ICF signature. * Serum hs-CRP level ≥2.0 mg/L and \<15 mg/L * Diagnosis of chronic kidney disease, eGFR ≥15 and \<60 mL/min/1.73 m2 or eGFR ≥60 mL/min/1.73m2 and UPCR\>200 mg/g * Received COVID-19 vaccine at least 30 days prior to the Screening visit, per participant verbal attestation. * Agreement to comply with contraception and reproduction restrictions Exclusion Criteria: * Clinical evidence or suspicion of active infection * Current or recent COVID-19 infection within 30 days * Serious infection within 6 months or more than 1 such episode within 18 months * Any history of a serious opportunistic infection within 18 months * Known history of immunodeficiency * History of gastrointestinal ulceration or perforation within 12 months * History of active diverticulitis, active inflammatory bowel disease, or GI abscess within 12 months * History of GI bleeding requiring hospitalization and/or transfusion within 6 months * New York Heart Association Class III or IV congestive heart failure and/or hospitalization for heart failure exacerbation within 6 months * Acute coronary syndrome, stroke, transient ischemic attack, or other thrombotic or thromboembolic event, or arterial revascularization procedure within 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C-reactive protein are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Hirschsprung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C-reactive protein Chronic kidney diseases Chronic kidney insufficiency Chronic renal diseases Chronic renal insufficiency High sensitivity C-reactive protein HS-CRP HSCRP Kidney insufficiency, chronic

Contacts and locations

Locations

  • Site - 0101

    Birmingham, Alabama, 35209, United States

  • Site - 0102

    Fort Mill, South Carolina, 29707, United States

  • Site - 0103

    Greenville, South Carolina, 29607, United States

  • Site - 0104

    Phoenix, Arizona, 85018, United States

  • Site - 0105

    Houston, Texas, 77043, United States

  • Site - 0106

    Chicago, Illinois, 60655, United States

  • Site - 0107

    San Antonio, Texas, 78212, United States

  • Site - 0108

    Knoxville, Tennessee, 37923, United States

  • Site - 0109

    Manassas, Virginia, 20110, United States

  • Site - 0110

    Charlotte, North Carolina, 28208, United States

  • Site - 0111

    Lampasas, Texas, 76550, United States

  • Site - 0112

    Valencia, California, 91355, United States

  • Site - 0113

    Greenacres City, Florida, 334667, United States

  • Site - 0114

    Council Bluffs, Iowa, 51501, United States

  • Site - 0115

    Morton, Illinois, 61550, United States

  • Site - 0117

    Fargo, North Dakota, 58104, United States

  • Site - 0119

    Port Orange, Florida, 32127, United States

  • Site - 0120

    Cincinnati, Ohio, 45219, United States

  • Site - 0122

    Savannah, Georgia, 31406, United States

  • Site - 0123

    Las Vegas, Nevada, 89121, United States

  • Site - 0125

    San Dimas, California, 91773, United States

  • Site - 0126

    Providence, Rhode Island, 02818, United States

  • Site - 0127

    Marion, Ohio, 43302, United States

  • Site - 0128

    Valencia, California, 91355, United States

  • Site - 0129

    Metairie, Louisiana, 70006, United States

  • Site - 0130

    Middletown, New York, 10940, United States

  • Site - 0132

    Bethlehem, Pennsylvania, 18017, United States

  • Site - 0134

    Kenosha, Wisconsin, 53144, United States

  • Site - 0135

    Huntsville, Alabama, 35763, United States

  • Site - 0136

    Stamford, Connecticut, 06905, United States

  • Site - 0141

    San Antonio, Texas, 78255, United States

  • Site - 0144

    Plantation, Florida, 33317, United States

  • Site - 0145

    Huntsville, Alabama, 35805, United States

  • Site - 0147

    Morgantown, West Virginia, 26505, United States

  • Site - 0148

    Greenville, Texas, 75402, United States

  • Site - 0149

    Pembroke Pines, Florida, 33024, United States

  • Site - 0150

    McKinney, Texas, 75069, United States

  • Site - 0151

    Tampa, Florida, 33634, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.